Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen

Bone Marrow Transplantation

Volumn 22, Issue 1, 1998, Pages 21-26

  Matsuyama, T ^a,b   Kojima, S ^a   Kato, K ^a  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^b NONE   (Japan)

Author keywords

Bone marrow transplantation; Childhood; Leukemia; Melphalan; Non TBI regimen

Indexed keywords

BUSULFAN; CYCLOSPORIN A; MELPHALAN; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DIARRHEA; DRUG TOXICITY; FEMALE; FEVER; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRANULOCYTOPENIA; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; STOMATITIS; SURVIVAL; THROMBOCYTOPENIA; VOMITING;

EID: 0031825581     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701276     Document Type: Article

References (36)

1. Nesbit ME, Buckley JD, Feig SA et al. Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group. J Clin Oncol 1994; 12: 127-135.
2. Ljungman P, Witte T, Verdonck L et al. Bone marrow transplantation for acute myeloblastic leukaemia: an EBMT leukaemia working party prospective analysis from HLA-typing. Br J Haematol 1993; 84: 61-66.
3. Amadori S, Testi AM, Aricò M et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol 1993; 11: 1046-1054.
4. Reiter A, Schrappe M, Ludwig WD et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM86. Blood 1994; 84: 3122-3133.
5. Smith M, Arthur D, Camitta B et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18-24.
6. Sanders JE, Thomas ED, Buckner CD et al. Marrow transplantation for children in first remission of acute nonlymphoblastic leukemia: an update. Blood 1985; 66: 460-462.
7. Liesner RJ, Leiper AD, Hann IM et al. Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. J Clin Oncol 1994; 12: 916-924.
8. Witherspoon RP, Fisher LD, Schoch G et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. New Engl J Med 1989; 321: 784-789.
9. Copelan EA, Biggs JC, Thompson JM et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 1991; 78: 838-843.
10. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
11. Maraninchi D, Pico JL, Hartmann O et al. High-dose melphalan with or without marrow transplantation: a study of dose-effect in patients with refractory and/or relapsed acute leukemias. Cancer Treat Rep 1986; 70: 445-448.
12. Helenglass G, Powels RL, McElwain TJ et al. Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission. Bone Marrow Transplant 1988; 3: 21-29.
13. Srivastava A, Bradstock KF, Szer J et al. Busulphan and melphalan prior to autologous bone marrow transplantation. Bone Marrow Transplant 1993; 12: 323-329.
14. Martino R, Badell I, Brunet S et al. High-dose busulfan and melphalan before bone marrow transplantation for acute nonlymphoblastic leukemia. Bone Marrow Transplant 1995; 16: 209-212.
15. Vey N, Prijck BD, Faucher C et al. A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies. Bone Marrow Transplant 1996; 18: 495-499.
16. Michel G, Gluckman E, Esperou-Bourdeau H et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation-a report from the Société Française de Greffe de Moelle. J Clin Oncol 1994; 12: 1217-1222.
17. Bueltzingsloewen A, Esperou-Bourdeau H, Souillet G et al. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a cooperative study of the Société Française de Greffe de Moelle. Bone Marrow Transplant 1995; 16: 521-527.
18. Vassal G, Deroussent A, Hartmann O et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990; 50: 6203-6207.
19. Powles RL, Morgenstern GR, Kay HEM et al. Mismatched family donors for bone marrow transplantation as treatment for acute leukaemia. Lancet 1983; i: 612-615.
20. D'Angio GJ, Seeger R, Strandjord S et al. Metastatic neuroblastoma managed by supralethal therapy and bone marrow reconstitution (BMRc). Results of a four-institution children's cancer study group pilot study. Prog Clin Biol 1985; 175: 557-563.
21. Graham-Pole J, Coccia P, Lazarus HM et al. High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and Ewing's sarcoma. Am J Pediatr Hematol Oncol 1984; 6; 17-26.
22. Singhal S, Powles R, Treleaven J et al. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women. Bone Marrow Transplant 1996; 18: 1049-1055.
23. Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versushost disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995; 15: 663-668.
24. Morishima Y, Morishita Y, Tanimoto M et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. Blood 1989; 74: 2252-2256.
25. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
26. Russell JA, Woodman RC, Poon MC et al. Addition of low-dose folinic acid to a methotrexate/cyclosporine A regimen for prevention of acute graft-versus-host disease. Bone Marrow Transplant 1994; 14: 397-401.
27. Morgan M, Dodds A, Atkinson K et al. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol 1991; 77: 529-534.
28. Jones RJ, Lee KSK, Beschorner WE et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
29. Thuret I, Michel G, Carla H et al. Long-term side-effects in children receiving allogeneic bone marrow transplantation in first complete remission of acute leukaemia. Bone Marrow Transplant 1995; 15: 337-341.
30. Wingard JR, Plotnick LP, Freemer CS et al. Growth in chil- dren after bone marrow transplantation: busulfan plus cyclophosphamide versus cyclophosphamide plus total body irradiation. Blood 1992; 79: 1068-1073.
31. Woods WG, Kobrinsky N, Buckley J et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study. J Clin Oncol 1993; 11: 1448-1457.
32. Shaw PJ, Bergin ME, Burgess MA et al. Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation. J Clin Oncol 1994; 12: 2138-2145.
33. Bordigoni P, Vernant JP, Souillet G et al. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia in first remission: a cooperative study of the Groupe d'Etude de la Greffe de Moelle Osseuse. J Clin Oncol 1989; 7: 747-753.
34. Locatelli F, Pession A, Bonetti F et al. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. Leukemia 1994; 8: 844-849.
35. Carpenter PA, Marshall GM, Giri N et al. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan. Bone Marrow Transplant 1996; 18: 489-494.
36. Tiedemann K, Waters KD, Tauro GP et al. Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission. Blood 1993; 82: 3730-3738.